Discovery of BI 224436, a Noncatalytic Site Integrase Inhibitor (NCINI) of HIV-1.
Fader, L.D., Malenfant, E., Parisien, M., Carson, R., Bilodeau, F., Landry, S., Pesant, M., Brochu, C., Morin, S., Chabot, C., Halmos, T., Bousquet, Y., Bailey, M.D., Kawai, S.H., Coulombe, R., LaPlante, S., Jakalian, A., Bhardwaj, P.K., Wernic, D., Schroeder, P., Amad, M., Edwards, P., Garneau, M., Duan, J., Cordingley, M., Bethell, R., Mason, S.W., Bos, M., Bonneau, P., Poupart, M.A., Faucher, A.M., Simoneau, B., Fenwick, C., Yoakim, C., Tsantrizos, Y.(2014) ACS Med Chem Lett 5: 422-427
- PubMed: 24900852 
- DOI: https://doi.org/10.1021/ml500002n
- Primary Citation of Related Structures:  
4NYF - PubMed Abstract: 
An assay recapitulating the 3' processing activity of HIV-1 integrase (IN) was used to screen the Boehringer Ingelheim compound collection. Hit-to-lead and lead optimization beginning with compound 1 established the importance of the C3 and C4 substituent to antiviral potency against viruses with different aa124/aa125 variants of IN. The importance of the C7 position on the serum shifted potency was established. Introduction of a quinoline substituent at the C4 position provided a balance of potency and metabolic stability. Combination of these findings ultimately led to the discovery of compound 26 (BI 224436), the first NCINI to advance into a phase Ia clinical trial.
Organizational Affiliation: 
Research and Development, Boehringer Ingelheim (Canada) Ltd. , 2100 Cunard Street, Laval, Québec H7S 2G5, Canada.